The open access paper provides details of the study, which is testing a potential new treatment for Palmo-Plantar Pustulosis (PPP).
A new paper has just been published describing the protocol for the APRICOT trial. APRICOT, which stands for Anakinra for Pustular psoriasis: Response in a Controlled Trial, is a trial to test a potential new drug treatment (Anakinra) for Palmo-Plantar Pustulosis (PPP) - pustular psoriasis of the palms of the hands and/or soles of the feet.
The paper is open access, which means it is available to view free of charge and without any barriers. You can read it here.
APRICOT is a clinical trial based at Guy’s Hospital, London, led by Professor Catherine Smith at St John’s Institute of Dermatology. The trial is testing whether the medication Anakinra is effective at treating PPP.
Recent research has shown that PPP may be caused by an abnormal pathway in the body's immune system, involving a protein called interleukin-1 (IL-1). Anakinra specifically blocks this IL-1 pathway. Daily treatment (injections) with Anakinra may therefore prove to be an effective way of reducing PPP symptoms. Anakinra is already licensed for use in other inflammatory conditions (such as rheumatoid arthritis) and has a good safety profile.
APRICOT collaborators, including the Psoriasis Association, have been involved in the project from the beginning and will also be instrumental in influencing the direction of the trial as part of the trial management group.
APRICOT is sponsored by Guy’s and St Thomas’ NHS Foundation Trust and is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership.
The APRICOT study has recently passed its 'half way recruitment target', however 32 new participants are still required to start as soon as possible. The trial is currently running at centres in Bradford, Bristol, Cambridge, Cardiff, Derby, Dudley, Dundee, Harlow, Lancaster, Liverpool, London, Newcastle, Norwich, Poole, and Salford. New centres in Chelmsford, Exeter, Fife, Glasgow, Nottingham and Sheffield are also due to open very soon.
If you have PPP and would like to take part in the study, you can register your interest here.